Edition:
United Kingdom

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

34.55USD
19 Oct 2018
Change (% chg)

$-0.95 (-2.68%)
Prev Close
$35.50
Open
$35.23
Day's High
$35.85
Day's Low
$33.67
Volume
70,196
Avg. Vol
80,542
52-wk High
$54.51
52-wk Low
$6.83

Summary

Name Age Since Current Position

Andrey Zarur

47 Chairman of the Board, Co-Founder

Martin Freed

57 2018 President, Director

Ilan Ganot

44 Chief Executive Officer, Co-Founder, Director

Jennifer Ziolkowski

44 2017 Chief Financial Officer, Treasurer and Assistant Secretary

Alvaro Amorrortu

46 Chief Operating Officer

Joel Schneider

33 2017 Chief Technology Officer and Head of Exploratory Research and Development

Carl Morris

46 2017 Chief Scientific Officer

Jorge Quiroz

48 Chief Medical Officer

Sukumar Nagendran

52 2018 Director

Matthew Arnold

48 Independent Director

Robert Huffines

Independent Director

Adam Koppel

48 2017 Independent Director

Rajeev Shah

40 2017 Independent Director

Adam Stone

38 2015 Independent Director

Lynne Sullivan

52 2015 Independent Director

Carlo Tanzi

2017 IR Contact Officer

Biographies

Name Description

Andrey Zarur

Dr. Andrey J. Zarur, Ph.D. is the Chairman of the Board, Co-Founder of the Company. Zarur is Co-Founder of the Comapny. He has been active in early stage life sciences companies for more than 20 years, and has participated in the creation of more than a dozen companies in the healthcare and clean energy sectors. He is also Chairman, CEO and Founder of GreenLight Biosciences and a partner at Kodiak Venture Partners, a venture capital firm specializing in the formation of early stage information and life technology investments. Prior to joining Kodiak Venture Partners, he was founder and CEO of BioProcessors, which was sold to Seahorse Biosciences in 2007. In addition to BioProcessors, he has led four life science companies from inception to exit. Dr. Zarur is also a co-founder and chairman of the board for Lumicell, and chairman of the board for Allegro Diagnostics. Dr. Zarur was named a Young Global Leader of the World Economic Forum in 2005. He is an Overseer of the Museum of Science in Boston and a Senior Lecturer at the Massachusetts Institute of Technology (MIT) Sloan School of Management. Dr. Zarur holds Masters of Science degrees and a Ph.D. in Chemical Engineering from MIT and undergraduate degrees from the National University of Mexico. Dr. Zarur is the author of several peer-reviewed articles and holds close to 100 provisional and issued patents.

Martin Freed

Dr. Martin I. Freed is the President, Director of the company. He has served as an independent consultant to several private pharmaceutical, biotechnology, and healthcare companies, specializing in clinical and general pharmaceutical development and clinical and regulatory strategy since February 2015. He co-founded and served as chief medical officer of Civitas Therapeutics, Inc. from December 2010 to October 2014 (acquired by Acorda Therapeutics, Inc. (“Acorda”)), and as senior vice president, clinical development of Acorda from October 2014 through January 2015. In addition, Dr. Freed has served as chief medical officer and has provided strategic and operational planning and execution, as well as medical leadership for clinical pharmacology and development strategy and preclinical development for multiple pharmaceutical companies throughout his career. These companies include Avila Therapeutics, Inc., Taligen Therapeutics, Inc., Adnexus Therapeutics, Inc. (acquired by Bristol-Myers Squibb) and Vitae Pharmaceuticals, Inc. Dr. Freed spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals or SmithKline Beecham, where he served numerous roles including vice president, clinical development and medical affairs in the metabolism therapeutic area. Dr. Freed currently serves on the board of directors of Dicerna Pharmaceuticals, Inc. and Sojournix, Inc., and previously served on the board of directors of InteKrin Therapeutics Inc. from 2007 to 2010. He has authored over 100 publications or presentations. Dr. Freed has been Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital. A Fellow of the American College of Physicians, Dr. Freed received his B.S. with distinction in biology from the University of Delaware and M.D. from Pennsylvania State University’s College of Medicine.

Ilan Ganot

Mr. Ilan Ganot is the Chief Executive Officer, Co-Founder, Director of the Company. He started Solid in 2013 to find treatments, and potentially a cure, for Duchenne muscular dystrophy, a disease that afflicts his son Eytani. Prior to starting Solid, Mr. Ganot was an investment banker at JPMorgan Chase in London, specializing in hedge fund driven equities business for the firm. Mr. Ganot also worked at Nomura Securities in London, Hong Kong and New York, where he managed relationships with investors and clients of the firm. Prior to Nomura, Mr. Ganot was a senior salesperson for Lehman Brothers’ European Equities business. Mr. Ganot embarked on a banking career after practicing law at the Israeli law-firm, Haim Zadok & Co, where his focus was private equity law and mergers and acquisitions. Prior to practicing law, Mr. Ganot was division head at Vir-Tech, a laser engraving business, and a captain in the Israel Defense Forces. Mr. Ganot received his MBA from London Business school and holds law and business degrees from the IDC in Herzliya, Israel.

Jennifer Ziolkowski

Ms. Jennifer Ziolkowski is the Chief Financial Officer, Treasurer and Assistant Secretary of the Company, since May 2017. Prior to joining us, she served as the Head of Sales Operations, North America for Philips Healthcare, a healthcare company, from 2014 to 2017 and as its Senior Director of Finance, North America from 2012 to 2014. Ms. Ziolkowski served as Controller of Medical Consumables and Sensors from 2010 to 2012, Director of Finance of Imaging Systems from 2008 to 2010, Senior Director of Finance and Corporate Controller from 2007 to 2008 at TransMedics, Inc., a medical device company, and held various finance and corporate development leadership positions at Cytyc Corporation, a medical technology company, from 2001 to 2007. From 1996 to 2001, Ms. Ziolkowski gained significant experience at PricewaterhouseCoopers LLP where she served as a Senior Transaction Services Consultant and as Audit Senior and Staff in the Boston Technology Group. Ms. Ziolkowski holds a B.S. in Accounting from Boston College and is a Certified Public Accountant.

Alvaro Amorrortu

Mr. Alvaro Amorrortu is the Chief Operating Officer of the Company. Prior to joining Solid Biosciences, Mr. Amorrortu spent more than a decade as a management consultant advising biopharmaceutical companies on a variety of strategic challenges, including overseeing large scale organizational transformations as well as designing strategies for assets and portfolios moving from early stages of development to commercial launch. His career as a strategist started at the Monitor Group, and then after a few years working for Inventiv Health (Campbell Alliance), moved to IMS Health. In addition, Mr. Amorrortu brings to Solid Biosciences, hands on experience managing operations. He held leadership positions in Bunge Group and Cargill subsidiaries, where he was responsible for running manufacturing facilities as well as complex engineering projects. Mr. Amorrortu received his M.B.A. with a major in Finance from The Wharton School and graduated from the Instituto Tecnologico de Buenos Aires, Argentina with an MS in Industrial Engineering.

Joel Schneider

Dr. Joel Schneider, Ph.D., is the Chief Technology Officer and Head of Exploratory Research and Development of the Company, since June 2017. Dr. Schneider also served as an Analyst from March 2014 to March 2015, a Director from March 2015 to January 2017 and our Vice President of Research and Development from January 2017 to June 2017. Prior to joining Solid, Dr. Schneider completed a postdoctoral fellowship at Harvard University in the Department of Stem Cell and Regenerative Biology from January 2013 to 2014. He holds a Ph.D. in Cell Biology and Molecular Medicine from Rutgers University and a B.A. in Biology from Brandeis University.

Carl Morris

Dr. Carl Morris, Ph.D., is the Chief Scientific Officer of the Company, since June 2017. Dr. Morris had previously served as our Senior Vice President of Research and Development from September 2015 to June 2017. Prior to joining us, Dr. Morris held various leadership positions within Pfizer Inc.’s Rare Disease Research Unit from January 2010 to August 2015, including serving as a Senior Director, Director and Senior Principal Scientist. Prior to Pfizer, Dr. Morris held various positions within the Tissue Repair unit at Wyeth Pharmaceuticals, Inc., a pharmaceutical company acquired by Pfizer. Dr. Morris was an Assistant Professor at Boston University School of Medicine and a founding faculty member of the Muscle and Aging Research Unit. He is also co-founder and a member of the board of directors of Breed Nutrition Inc. Dr. Morris holds a B.A. in Biology from Franklin Pierce College and a Ph.D. in Physiology from UCLA.

Jorge Quiroz

Mr. Jorge A. Quiroz, M.D. is the Chief Medical Officer of the Company. He provides leadership and clinical vision for the company, as well as being responsible for the clinical programs in patients with DMD. Prior to joining Solid, Dr. Quiroz served as the Head of Neurodevelopment & Psychiatry, Translational Medicine Neurosciences at Hoffmann-La Roche. A medical graduate from the Pontifical Catholic University of Chile and Board Certified Psychiatrist, he completed his medical training as a Research Fellow at the Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, at the National Institutes of Health in Bethesda, Maryland. He also holds a Master of Business Administration dual degree from Columbia University & London Business School. Dr. Quiroz received the NARSAD Young Investigator Award, the NCDEU New Investigator Award, the Fellows Award for Research Excellence, and the NIH Clinical Center Director’s Award, among other distinctions. He has designed and conducted numerous proof of concept studies, including studies in orphan designated indications, and has successfully filed New Drug Applications with the FDA during his tenure at Johnson & Johnson Pharmaceutical Research and Development and Hoffmann-La Roche. Dr. Quiroz has published over 45 peer reviewed scientific publications and book chapters in the fields of translational neurosciences and drug development.

Sukumar Nagendran

Dr. Sukumar Nagendran, M.D. is the Director of the Company. He was most recently the Chief Medical Officer & Senior Vice President of AveXis Inc., prior to the company’s acquisition by Novartis. There, he was responsible for overseeing and driving all clinical development and medical affairs strategy, notably for the company’s late-stage AAV-mediated gene therapy program for Spinal Muscular Atrophy (SMA). In his role, Dr. Nagendran also led the company’s interactions with experts in the gene therapy field and helped manage relationships with the investment and rare disease communities. Prior to AveXis, Dr. Nagendran held key leadership positions at Pfizer, Novartis, Daiichi Sankyo, Reata Pharmaceuticals and Quest Diagnostics. During his tenures at these companies, Dr. Nagendran played significant roles in several high-profile product launches and across multiple functions, including clinical trials/operations, field medical, medical product teams, pricing and reimbursement, publications, and advocacy. He was also instrumental in building the medical affairs department at Quest Diagnostics, one of the leading lab/diagnostics providers in the world. Prior to moving to the biotech industry, Dr. Nagendran practiced internal medicine, with a focus on diabetes and cardiovascular disease. He is a Mayo Alumni Laureate and founding member of the Robert Wood Johnson Legacy Society. He is also the sponsor for the Fonseca-Nagendran Scholar award at the American Diabetes Association (ADA) to enhance research in minority populations. Dr. Nagendran received his undergraduate degree in Biochemistry at Rutgers University and his M.D. at Rutgers Medical School and trained in Internal Medicine at Mayo Clinic, Rochester.

Matthew Arnold

Mr. Matthew Arnold is an Independent Director of the Company. Mr. Arnold is a founding member of Solid and has served as a member of our board of directors since our inception in 2013. A former energy executive, since 2009, Mr. Arnold has been actively working with startup businesses in the United Kingdom and Europe, primarily in the technology and clean tech sectors. He holds an M.S. from the University of Virginia and a B.A. from Duke University. Mr. Arnold is qualified to serve on our board of directors because of his extensive management and board experience with startup companies and his background in finance.

Robert Huffines

Mr. Robert Huffines is an Independent Director of the Company. Mr. Huffines has served as a member of our board of directors since December 2013. Mr. Huffines joined J.P. Morgan, a leading global financial services firm, in 1992 and currently serves as the Global Chairman of Investment Banking, a position he has held since February 2017. Throughout his career at J.P. Morgan, Mr. Huffines has held various leadership positions, including serving as Co-Head of the Global Healthcare Investment Banking Group from 2002 to 2010 and Vice Chairman from 2011 to January 2017. Mr. Huffines received an M.B.A. from the University of Virginia and a B.A. from the University of North Carolina. Mr. Huffines is qualified to serve on our board of directors based on his over 25 years of experience advising healthcare companies and his leadership experience.

Adam Koppel

Dr. Adam Koppel, M.D., Ph.D., is an Independent Director of the Company. Dr. Koppel has served as a member of our board of directors since October 2017. Dr. Koppel rejoined Bain Capital, a global investment firm, in 2016 as a Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003 where he was a leader within the healthcare sector until mid-2014. During the period from mid-2014 to mid-2016, Dr. Koppel worked at Biogen Inc., or Biogen, a biotechnology company, where he served as EVP of Corporate Development and Chief Strategy Officer. Prior to joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey & Co., a management consulting firm, where he served a variety of healthcare companies. Dr. Koppel currently serves on the board of directors of Trevena, Inc. and Dicerna Pharmaceuticals, Inc., both public companies. Dr. Koppel received an M.D. and Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine. He also received an M.B.A. from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an A.B. and A.M. in History and Science. Dr. Koppel is qualified to serve on our board of directors because of his extensive leadership experience, his public company board experience and his experience working in the healthcare sector.

Rajeev Shah

Mr. Rajeev Shah is an Independent Director of the Company. Mr. Shah has served as a member of our board of directors since March 2017. Mr. Shah has been Managing Director and Portfolio Manager at RA Capital Management, LLC, or RA Capital, an investment management company. Prior to joining RA Capital in 2004, Mr. Shah was a Senior Project Leader at Altus Pharmaceuticals Inc., a spin-off of Vertex Pharmaceuticals Inc., from 2001 to 2004. Mr. Shah is currently a member of the board of directors of Ra Pharmaceuticals, Inc. and Kalvista Pharmaceuticals, Inc., both public companies. Mr. Shah holds a B.A. in Chemistry from Cornell University. Mr. Shah is qualified to serve on our board of directors because of his extensive leadership experience, his public company board experience and his experience investing in life science companies.

Adam Stone

Mr. Adam Stone is an Independent Director of the Company. Mr. Stone has served as a member of our board of directors since November 2015. Mr. Stone is currently the Chief Investment Officer of Perceptive Advisors, a life science focused hedge fund, where he has worked since May 2006. Mr. Stone received a B.A. from Princeton University. Mr. Stone is qualified to serve on our board of directors because of his extensive experience developing early-stage biotech and health care companies.

Lynne Sullivan

Ms. Lynne Sullivan is an Independent Director of the Company. Ms. Sullivan has served as a member of our board of directors since November 2015. Since September 2016, Ms. Sullivan has served as Biogen’s Senior Vice President of Finance, where she also served as Vice President of Tax and Corporate Finance from February 2015 to March 2016 and Vice President of Tax from April 2008 to February 2015. Ms. Sullivan is currently a member of the board of directors of resTORbio, Inc., a public company. She received an M.S. in Taxation from Bentley University and a B.S.B.A. from Suffolk University. Ms. Sullivan is a Certified Public Account for over 20 years. Ms. Sullivan is qualified to serve on our board of directors because of her extensive experience in public accounting and financial expertise.

Carlo Tanzi